The next EU research funding programme should be doubled in size to help fix Europe's growth problems, according to former World Trade Organization chief Pascal Lamy, who is chairing a group of experts selected by the European Commission to analyse which changes to make after the current programme expires in 2020.
Now that you have published your report, what would you like to see as the top priorities for the next framework programme?
‘Our mandate was not about the budget allocation game. But we are making the case for a much more resourceful programme. Our proposal is to double ‘FP9’ from the current EUR 77 billion programme known as Horizon 2020. EUR 120 billion would be a bare minimum for the next programme. This is a big increase, but I believe it’s necessary with where the world is going.
‘It is a well-known fact that we must invest more in R&I (research and innovation) because we are moving to an economy that is more and more dematerialised where brain juice and talent will be the main resource. That is something we know, but we have a problem with speed because other countries like the US, China, Japan and Korea are investing more than we do. We have to catch up.’
Horizon 2020 was already the EU’s biggest research programme ever. What things should change?
‘We need to pay more attention to the gap we have in Europe between what we produce in science and what we produce in innovation (new products and services). This is nothing new, we’ve been saying it for quite a bit of time, but we are pretty clear that in the future we definitely need to close this gap. It’s been there too long, it’s too large and it’s too much of a drag on future European growth so a big effort must be made. Not only in turning money into science, but in turning science into money.’
‘We are moving to an economy that is more and more dematerialised where brain juice and talent will be the main resource.’
Pascal Lamy, former World Trade Organization Director-General
There is also a big research gap between Western and Eastern Europe, how can we close that?
‘A number of the newer EU members have not reached the scientific capacity of older members. That’s something Horizon 2020 has been working on, devoting part of research funds on increasing capacity in some countries, while part of the ESIF (European Structural and Investment Funds) supports building up science and innovation excellence.
‘We need more efforts on both sides. I would recommend that this articulation is improved because having researchers doing something on one side, and regions doing things on the other, doesn’t automatically fit and so sometimes they don’t work alongside each other. We listened to Commissioners Creţu (Regional Policy), Katainen (Jobs, Growth, Investment and Competitiveness), Šefčovič (Energy Union) and Vestager (Competition), because these policies can work better together and contribute more to beefing up science and innovation capacity in many regions.’
Now the report is published, what happens next?
‘We enter a period where there will be a wider public debate on what to do with the next framework programme. This will be triggered by our report and by the discussion in 2018 about the next MFF (multi-annual financial framework, the overall EU budget). The proportion of resources which are needed will be part of the next financial priorities of the EU.’
How optimistic are you that recommendations of the group you are chairing, known as the High Level Group (HLG), will be implemented into the next R&I fund?
‘This is a very political exercise. We have been asked to contribute as experts. It’s now up to a public debate between democratically legitimised institutions – the European Council, Parliament and Commission.
‘What I know is that we have structured our jobs so that our work does not stop today, when we will disclose the findings of our report at a big conference organised by DG RTD (Directorate-General for Research and Innovation) in Brussels (Belgium). We will remain involved in moving our recommendations forward. The variety and diversity of the HLG, where you have people coming from all horizons of the research and innovation ecosystem, is an asset in order to address this.
‘We all know we have a growth problem which fuels a number of social problems. We need more growth and given where we are with demographics, which is a shrinking population, the only way to get more growth is with more R&I, it’s as simple as that.’
If you liked this article, please consider sharing it on social media.
Self-driving cars are set to bring one of the biggest changes to our global transportation system in decades, but their potential to increase road safety should not be over-emphasised if we want to increase people’s trust in automated vehicles, says Dr Jean-François Bonnefon from the Toulouse School of Economics, France, and Massachusetts Institute of Technology, US. He is a behavioural scientist who studies the ethics of self-driving cars and is speaking at the European Conference on Connected and Automated Driving (EUCAD) in Brussels, Belgium, which runs from 2-3 April 2019.
Nearly 100 years ago scientists developed a vaccine for tuberculosis (TB). Today, there are 10 million new cases worldwide and 1.6 million deaths from the disease every year. Increasingly, these cases are becoming difficult to treat as the bug that causes the disease can be resistant to antibiotics. However, several new TB vaccines are under development and there is growing optimism that a new vaccine will emerge, says Helen McShane, professor of vaccinology at Oxford University, UK. This could save millions of lives, she said, but more work is needed to reassure the general public that vaccines are safe and effective.
In remote, rural corners of Malawi, hospitals are often faced with life-and-death decisions. Women in need of emergency caesarean sections, older people with hernias, and children with appendicitis need surgery. But should they be rushed to the operating theatre or transferred to specialists in city hospitals?
Mice that have undergone weight loss surgery experience a change in the composition of their gut bacteria and the functioning of their genes, leading scientists to explore the possibility of mimicking these changes to develop a non-surgical treatment for obesity and liver disease in humans.
Technology is helping to improve healthcare in sub-Saharan Africa.
Unexpected effects of bariatric surgery could help develop non-surgical obesity treatments.
We should not over-promise about the safety of automated vehicles if we want people to trust them, says Dr Jean- François Bonnefon.